Abdel Babiker

发表

Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop‐outs

Nikos Pantazis, Giota Touloumi, A. S. Walker, 2005 .

Comments on design and monitoring of survival trials in complex scenarios.

Patrick Royston, Abdel Babiker, Mahesh Kb Parmar, 2019, Statistics in medicine.

strbee: Randomization-based Efficacy Estimator

Abdel Babiker, Ian R. White, Sarah Walker, 2002 .

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts

Santiago Pérez-Hoyos, J Darbyshire, Andrew N. Phillips, 2001 .

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

Abdel Babiker, Rodolphe Thiébaut, Andrew Phillips, 2010, Clinical trials.

Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies

Jim Young, Kholoud Porter, Abdel Babiker, 2010, PLoS medicine.

Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom

John P. Walsh, Andrew N. Phillips, Steve Kaye, 2007, AIDS.

Structured Observations Reveal Slow HIV-1 CTL Escape

Angela R. McLean, Abdel Babiker, John Frater, 2015, PLoS genetics.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Anne M Johnson, Kholoud Porter, Nikos Pantazis, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study

Abdel Babiker, Norman Markowitz, D. Wentworth, 2012, PloS one.

Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

Abdel Babiker, Janet Darbyshire, James D Neaton, 2010, Clinical trials.

Joint modelling of bivariate longitudinal data with informative dropout and left‐censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection

Hélène Jacqmin-Gadda, Abdel Babiker, Rodolphe Thiébaut, 2005, Statistics in medicine.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.

Effect estimates in randomized trials and observational studies: comparing apples with apples.

Haitao Chu, Kholoud Porter, Stephen R Cole, 2019, American journal of epidemiology.

Short-course antiretroviral therapy in primary HIV infection.

Steve Kaye, Kholoud Porter, Helen Rees, 2013, The New England journal of medicine.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART

Kholoud Porter, Abdel Babiker, A Sarah Walker, 2003, The Lancet.

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation

Haitao Chu, Stephen R Cole, Roger Logan, 2016, AIDS.